[go: up one dir, main page]

DE69218624D1 - Behandlung von peridontalkrankheiten mit alendronat - Google Patents

Behandlung von peridontalkrankheiten mit alendronat

Info

Publication number
DE69218624D1
DE69218624D1 DE69218624T DE69218624T DE69218624D1 DE 69218624 D1 DE69218624 D1 DE 69218624D1 DE 69218624 T DE69218624 T DE 69218624T DE 69218624 T DE69218624 T DE 69218624T DE 69218624 D1 DE69218624 D1 DE 69218624D1
Authority
DE
Germany
Prior art keywords
alendronate
treatment
periodontal disease
peridontal diseases
peridontal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69218624T
Other languages
English (en)
Other versions
DE69218624T2 (de
Inventor
Barry J Gertz
Gideon A Rodan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE69218624D1 publication Critical patent/DE69218624D1/de
Publication of DE69218624T2 publication Critical patent/DE69218624T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69218624T 1991-12-17 1992-12-08 Behandlung von peridontalkrankheiten mit alendronat Expired - Fee Related DE69218624T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/808,701 US5270365A (en) 1991-12-17 1991-12-17 Prevention and treatment of periodontal disease with alendronate
PCT/US1992/010534 WO1993011774A1 (en) 1991-12-17 1992-12-08 Treatment of periodontal disease with alendronate

Publications (2)

Publication Number Publication Date
DE69218624D1 true DE69218624D1 (de) 1997-04-30
DE69218624T2 DE69218624T2 (de) 1997-08-07

Family

ID=25199466

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69218624T Expired - Fee Related DE69218624T2 (de) 1991-12-17 1992-12-08 Behandlung von peridontalkrankheiten mit alendronat

Country Status (22)

Country Link
US (1) US5270365A (de)
EP (1) EP0617624B1 (de)
JP (1) JP2825654B2 (de)
KR (1) KR100258667B1 (de)
AT (1) ATE150646T1 (de)
AU (1) AU675417B2 (de)
CA (1) CA2122498A1 (de)
CY (1) CY2054B1 (de)
CZ (1) CZ282902B6 (de)
DE (1) DE69218624T2 (de)
DK (1) DK0617624T3 (de)
ES (1) ES2100519T3 (de)
GR (1) GR3022951T3 (de)
HK (1) HK1000114A1 (de)
HU (1) HU221807B1 (de)
IL (1) IL104109A (de)
LV (1) LV12084B (de)
NO (1) NO306197B1 (de)
NZ (1) NZ246274A (de)
SK (1) SK280628B6 (de)
WO (1) WO1993011774A1 (de)
ZA (1) ZA929712B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696427B1 (en) 1998-12-23 2004-02-24 Jomaa Pharmaka Gmbh Use of bisphosphonates for the prevention and treatment of infectious processes

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW237386B (de) * 1992-04-15 1995-01-01 Ciba Geigy
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
WO1995028145A1 (en) * 1994-04-18 1995-10-26 The Procter & Gamble Company Iontophoretic delivery of bisphosphonates to the alveolar bone
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
JP3411690B2 (ja) * 1994-09-21 2003-06-03 帝人株式会社 局所投与用アレンドロン酸ナトリウム製剤
CA2212996A1 (en) * 1995-02-17 1996-08-22 Merck & Co., Inc. Method of lessening the risk of non-vertebral bone fractures
CA2219354A1 (en) * 1995-05-12 1996-11-14 Merck & Co., Inc. Prevention of tooth loss by the administration of alendronate or its salts
CA2245793A1 (en) * 1996-02-14 1997-08-21 Itzhak Binderman Topical bisphosphonates for prevention of bone resorption
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
ES2210529T3 (es) * 1996-05-17 2004-07-01 MERCK & CO., INC. Formulacion de bisfosfonato efervescente.
EP1378234A1 (de) * 1996-05-17 2004-01-07 MERCK & CO. INC. Biphosphonat-Formulierung mit Brausewirkung
HUP0000125A3 (en) * 1996-10-04 2001-04-28 Merck & Co Inc Liquid alendronate formulations and producing them
US5773429A (en) * 1996-12-11 1998-06-30 Fuisz Technologies Ltd. Drug combination for treating calcium loss
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
EP1132088A3 (de) * 1997-07-22 2002-04-24 MERCK & CO. INC. Methode zur Inhibierung der Knochenresorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
FR2784031B1 (fr) * 1998-10-02 2002-02-01 Sanofi Elf Utilisation de derives de l'acide bisphosphonique pour la preparation d'un medicament destine au traitement des boiteries
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US6143919A (en) * 1999-05-18 2000-11-07 3M Innovative Properties Company Polymerizable acidic compounds and methods of preparation
US6315566B1 (en) 1999-05-18 2001-11-13 3M Innovative Properties Company Dental materials
PL196485B1 (pl) * 2000-05-11 2008-01-31 Inst Farmaceutyczny Stała doustna kompozycja farmaceutyczna zawierająca aminową pochodną kwasu bisfosfonowego i sposób jej wytwarzania
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
US20040053968A1 (en) * 2001-12-28 2004-03-18 Hartman George D. Methods and compositions for treating peridontal disease
US7960054B2 (en) * 2002-01-10 2011-06-14 Excellatron Solid State Llc Packaged thin film batteries
US20070094865A1 (en) * 2002-01-10 2007-05-03 Ji-Guang Zhang Packaged thin film batteries and methods of packaging thin film batteries
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
JP2005531532A (ja) * 2002-04-05 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド アレンドロナートおよびビタミンｄ製剤を用いる骨吸収阻害法
FR2838339B1 (fr) * 2002-04-12 2005-06-24 Univ Angers Derives poly-phosphonates pour compositions dentifrices
US20040137058A1 (en) * 2002-07-09 2004-07-15 Katdare Ashok V. Effervescent bisphosphonate formulation
US20050142185A1 (en) * 2003-12-29 2005-06-30 Beleno Alfredo B. Softgel formulations of bisphosphonates bone resorption inhibitors
US20060034921A1 (en) * 2004-01-05 2006-02-16 Katdare Ashok V Effervescent bisphosphonate formulation
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20080070087A1 (en) * 2004-02-20 2008-03-20 Excellatron Solid State, Llc Non-volatile cathodes for lithium oxygen batteries and method of producing same
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
KR100564628B1 (ko) * 2004-06-16 2006-03-28 삼성전자주식회사 스플릿 게이트형 플래쉬 메모리 소자 및 그 제조방법
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
WO2007044904A2 (en) * 2005-10-11 2007-04-19 Ji-Guang Zhang Method of manufacturing lithium battery
US20070087052A1 (en) * 2005-10-19 2007-04-19 Katdare Ashok V Effervescent bisphosphonate formulation
WO2007106742A2 (en) 2006-03-10 2007-09-20 Excellatron Solid State Llc Air battery and manufacturing method
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
BR112012002551A2 (pt) 2009-08-03 2017-06-13 Chimerix Inc composição e métodos de tratamento de infecções virais e tumores induzidos por vírus
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
RU2449761C1 (ru) * 2011-03-09 2012-05-10 Светлана Минифаритовна Алетдинова Способ лечения хронических апикальных периодонтитов
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
RU2713257C1 (ru) * 2019-05-06 2020-02-04 Жанна Владимировна Вечеркина Способ лечения хронического апикального периодонтита

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3429963A (en) * 1964-06-09 1969-02-25 Colgate Palmolive Co Dental preparation containing polymeric polyelectrolyte
US4134969A (en) * 1974-02-04 1979-01-16 Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) Method of treatment of calcium disorders using aminoalkane-diphosphonic acids
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4042679A (en) * 1975-11-07 1977-08-16 Colgate-Palmolive Company Antibacterial oral composition
US4138477A (en) * 1976-05-28 1979-02-06 Colgate Palmolive Company Composition to control mouth odor
US4440779A (en) * 1981-06-30 1984-04-03 Merck & Co., Inc. Tricyclic derivatives of substituted pyrrole acids as analgesic and anti-inflammatory agents
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
US4677132A (en) * 1986-03-12 1987-06-30 American Home Products Corporation Inhibition of bone resorption by etodolac
EP0272208B1 (de) * 1986-11-21 1991-06-12 Ciba-Geigy Ag Aromatisch substituierte Azacyclo-alkylalkandiphosphonsäuren
DE3768463D1 (de) * 1986-11-21 1991-04-11 Ciba Geigy Ag Neue substituiertaminomethandiphosphonsaeuren.
HU199151B (en) * 1987-03-10 1990-01-29 Yamanouchi Pharma Co Ltd Process for producing bis-phosphonic acid derivatives
US4816437A (en) * 1987-06-01 1989-03-28 Trustees Of Boston University Methods for inducing general and localized bone apposition in-vivo
EP0317505A1 (de) * 1987-11-13 1989-05-24 Ciba-Geigy Ag Neue Azacycloalkylalkandiphosphonsäuren
GB8726714D0 (en) * 1987-11-14 1987-12-16 Beecham Group Plc Compounds
ES2054868T3 (es) * 1987-12-11 1994-08-16 Ciba Geigy Ag Acidos aralifatilaminoalcanodifosfonicos.
US4877603A (en) * 1987-12-18 1989-10-31 The Procter & Gamble Company Oral compositions
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4990503A (en) * 1988-08-12 1991-02-05 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclic bisphosphonic acid derivatives
CA2035179C (en) * 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
GB9008433D0 (en) * 1990-04-12 1990-06-13 Beecham Group Plc Novel compositions
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696427B1 (en) 1998-12-23 2004-02-24 Jomaa Pharmaka Gmbh Use of bisphosphonates for the prevention and treatment of infectious processes

Also Published As

Publication number Publication date
SK72794A3 (en) 1995-04-12
SK280628B6 (sk) 2000-05-16
LV12084A (lv) 1998-07-20
NO942267L (no) 1994-06-16
CZ282902B6 (cs) 1997-11-12
EP0617624B1 (de) 1997-03-26
DE69218624T2 (de) 1997-08-07
JPH07502506A (ja) 1995-03-16
AU675417B2 (en) 1997-02-06
WO1993011774A1 (en) 1993-06-24
JP2825654B2 (ja) 1998-11-18
HK1000114A1 (en) 1997-12-05
US5270365A (en) 1993-12-14
HUT68788A (en) 1995-07-28
AU3242093A (en) 1993-07-19
NO942267D0 (no) 1994-06-16
NZ246274A (en) 1997-02-24
KR940703676A (ko) 1994-12-12
NO306197B1 (no) 1999-10-04
DK0617624T3 (da) 1997-04-21
IL104109A (en) 1997-02-18
CA2122498A1 (en) 1993-06-24
LV12084B (en) 1998-11-20
HU9401378D0 (en) 1994-08-29
KR100258667B1 (ko) 2000-07-01
HU221807B1 (hu) 2003-01-28
GR3022951T3 (en) 1997-06-30
ES2100519T3 (es) 1997-06-16
CZ148794A3 (en) 1995-03-15
ZA929712B (en) 1993-06-14
CY2054B1 (en) 1998-04-30
IL104109A0 (en) 1993-05-13
ATE150646T1 (de) 1997-04-15
EP0617624A1 (de) 1994-10-05

Similar Documents

Publication Publication Date Title
ATE150646T1 (de) Behandlung von peridontalkrankheiten mit alendronat
EP0662075A4 (de) Prostaglandin-analoga zur behandlung von osteoporose.
DE3867736D1 (de) Methylenphosphonalkylphosphinate, pharmazeutische zubereitungen und verfahren zur behandlung abnormalen kalzium- und phosphat-stoffwechsels.
ATE289199T1 (de) Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
NO933044L (no) Fremgangsmaate for behandling av osteoporose
SE8704248D0 (sv) Medical use
ATE129155T1 (de) Verwendung von phosphatidylglycerol(dic 18:10) zur behandlung obstruktiver atemwegserkrankungen.
ATE174221T1 (de) Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
ES2136167T3 (es) Composiciones de idebenona para tratar la enfermedad de alzheimer.
ATE137116T1 (de) Behandlung von entzündlichen erkrankungen mit 15- ketoprostaglandinen
DK0994884T3 (da) Diphosphonsyresalte til behandling af osteoporose
EE9600191A (et) Püridüülbisfosfonaatide kasutamine terapeutiliste toimeainetena
ATE135681T1 (de) Diclofenac-cholinsalz, verfahren zur herstellung und pharmazeutische zusammensetzungen, die es enthalten
DE69301750D1 (de) Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
KR970705400A (ko) 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone)
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE69214647D1 (de) Verwendung von atipamezol zur behandlung der männlichen sexuellen impotenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee